The U.S. Food and Drug Administration (FDA) has granted orphan drug status to an experimental treatment from Imviva Biotech, marking a significant milestone in the fight against T-cell blood cancers. This treatment, known as CTD402, is a CAR T-cell therapy designed to target and eliminate aggressive forms of blood cancer, specifically relapsing/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL).
In a clinical trial, over 60% of patients experienced a remarkable complete response, meaning all signs of cancer disappeared. This groundbreaking achievement highlights the potential of CTD402 to revolutionize treatment options for patients with these rare and aggressive blood cancers. The trial, called TENACITY-01, is currently enrolling patients across the U.S., with the first participant dosed at the end of last year.
CTD402 is an allogeneic CAR T-cell therapy, meaning it utilizes immune T-cells from healthy donors. These cells are engineered to express a chimeric antigen receptor (CAR) that specifically targets CD7, a protein found on T-cells. This modification enhances the T-cells' ability to locate and destroy cancer cells, making it a powerful tool in the fight against T-cell blood cancers.
One of the key advantages of CTD402 is its off-the-shelf availability, which eliminates manufacturing delays that can be life-threatening for patients with rapidly progressive diseases. Unlike autologous therapies, which use a patient's own T-cells, CTD402 offers immediate treatment, providing a faster and potentially more effective approach.
The FDA's orphan drug designation for CTD402 comes with significant benefits, including reduced regulatory submission fees and tax credits, as well as seven years of market exclusivity if the therapy is approved. This recognition further emphasizes the potential of CTD402 to change the treatment paradigm for these rare and aggressive blood cancers.
Imviva's Chief Medical Officer, Dr. Jan Davidson-Moncada, expressed enthusiasm about the designation, stating that it supports the belief that an off-the-shelf CAR T therapy has the potential to transform treatment for rapidly progressing diseases. The company's manufacturing process has demonstrated product consistency across multiple donors and production lots, adding to the confidence in CTD402's effectiveness.
The TENACITY-01 trial is an open-label study, meaning both researchers and participants know the therapy being administered. It aims to assess the safety and effectiveness of CTD402 in adults and adolescents aged 12 and older with treatment-resistant or recurrent T-ALL/LBL. The trial's primary goals include evaluating the treatment's safety and the proportion of patients achieving a complete response after six months.
Additionally, the study will investigate the cellular pharmacokinetics of CTD402, examining how many T-cells multiply and how long they remain in a patient's blood. The FDA has previously granted rare pediatric disease designation and regenerative medicine advanced therapy designation to CTD402 for relapsed or refractory T-ALL, further emphasizing its potential impact on rare diseases affecting children.
Imviva's positive response to the orphan drug designation reflects the company's belief in CTD402's transformative potential. Dr. Davidson-Moncada emphasized that the designation supports the idea that an off-the-shelf CAR T therapy can revolutionize treatment for rapidly progressing diseases, marking a significant step forward in the field of cancer research and treatment.
